Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025LW" target="_blank" >RIV/61988987:17110/20:A21025LW - isvavai.cz</a>

Alternative codes found

RIV/00843989:_____/20:E0108388

Result on the web

<a href="https://www.nature.com/articles/s41408-020-0300-y.pdf" target="_blank" >https://www.nature.com/articles/s41408-020-0300-y.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41408-020-0300-y" target="_blank" >10.1038/s41408-020-0300-y</a>

Result language

angličtina

Original language name

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis

Original language description

The phase 3 A.R.R.O.W. study demonstrated that treatment with once-weekly carfilzomib (70 mg/m(2)) and dexamethasone (once-weekly Kd70 mg/m(2)) improved progression-free survival compared with twice-weekly carfilzomib (27 mg/m(2)) and dexamethasone (twice-weekly Kd27 mg/m(2)) in patients with relapsed and refractory multiple myeloma (RRMM; median, 11.2 versus 7.6 months; hazard ratio [HR] = 0.69; 95% confidence interval, 0.54-0.88; P = 0.0029). Once-weekly dosing also improved response rates and depth of response. We performed a subgroup analysis from A.R.R.O.W. according to age (<65, 65-74, or >= 75 years), renal function (creatinine clearance <50, >= 50-<80, or >= 80 mL/min), number of prior therapies (2 or 3), and bortezomib-refractory status (yes or no). Compared with twice-weekly Kd27 mg/m(2), once-weekly Kd70 mg/m(2) reduced the risk of progression or death (HR = 0.60-0.85) and increased overall response rates in nearly all the examined subgroups, consistent with reports in the overall A.R.R.O.W. population. The safety profiles of once-weekly Kd70 mg/m(2) across subgroups were also generally consistent with those in the overall population. Findings from this subgroup analysis generally demonstrate a favorable benefit-risk profile of once-weekly Kd70 mg/m(2), further supporting once-weekly carfilzomib dosing as an appropriate treatment option for patients with RRMM, regardless of baseline patient and disease characteristics.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood Cancer Journal

ISSN

2044-5385

e-ISSN

—

Volume of the periodical

10

Issue of the periodical within the volume

3

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

—

UT code for WoS article

000521002600002

EID of the result in the Scopus database

—